Ignite Creation Date:
2024-05-06 @ 3:02 AM
Last Modification Date:
2024-10-26 @ 11:27 AM
Study NCT ID:
NCT02191930
Status:
COMPLETED
Last Update Posted:
2022-08-08
First Post:
2014-07-11
Brief Title:
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
Sponsor:
University of Cologne
Organization:
University of Cologne
Study Overview
Official Title:
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BVB
Brief Summary:
The purpose of this trial is to determine
1 Objective response rate ORR defined as the proportion of patients having CR CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy
2 Progression-free survival PFS 3 years after registration
1 Objective response rate ORR defined as the proportion of patients having CR CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy
2 Progression-free survival PFS 3 years after registration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None